2022
SGLT2i Improves Glycemic Control in Patients With Congenital Severe Insulin Resistance.
Galderisi A, Tamborlane W, Taylor SI, Attia N, Moretti C, Barbetti F. SGLT2i Improves Glycemic Control in Patients With Congenital Severe Insulin Resistance. Pediatrics 2022, 150 PMID: 35652305, DOI: 10.1542/peds.2021-055671.Peer-Reviewed Original ResearchConceptsRabson-Mendenhall syndromeGlycemic controlHemoglobin A1cRenal calcium excretionInsulin-resistant diabetesSevere insulin resistanceCalcium excretionUrinary calciumAntidiabetic treatmentDay doseDose escalationSecond patientFirst patientInsulin levelsInsulin resistanceUrinary excretionSerum glucosePatientsEmpagliflozinMild increaseDapagliflozinΒ-hydroxybutyrateTarget rangeA1CExcretionLong-term Continuous Glucose Monitor Use in Very Young Children With Type 1 Diabetes: One-Year Results From the SENCE Study
Van Name MA, Kanapka LG, DiMeglio LA, Miller KM, Albanese-O’Neill A, Commissariat P, Corathers SD, Harrington KR, Hilliard ME, Anderson BJ, Kelley JC, Laffel LM, MacLeish SA, Nathan BM, Tamborlane WV, Wadwa RP, Willi SM, Williams KM, Wintergerst KA, Woerner S, Wong JC, DeSalvo DJ. Long-term Continuous Glucose Monitor Use in Very Young Children With Type 1 Diabetes: One-Year Results From the SENCE Study. Journal Of Diabetes Science And Technology 2022, 17: 976-987. PMID: 35343269, PMCID: PMC10348002, DOI: 10.1177/19322968221084667.Peer-Reviewed Original ResearchConceptsFamily behavioral interventionsContinuous glucose monitoringBlood glucose monitoringCGM useYoung childrenGlucose monitoringOne-year resultsType 1 diabetesContinuous glucose monitor useHemoglobin A1cCGM groupGlycemic outcomesType 1Behavioral interventionsExtension phaseBGM groupMonitor useOne-year studyCGM technologyDiabetes technologyGlycemiaHypoglycemiaChildrenBehavioural supportGroup
2019
Impact of Switching Youth With Diabetes to Insulin Degludec in Clinical Practice
Elahi S, Patel AD, Guandalini C, Steffen A, Sherr J, Tamborlane WV, Van Name MA. Impact of Switching Youth With Diabetes to Insulin Degludec in Clinical Practice. Endocrine Practice 2019, 25: 226-229. PMID: 30913005, DOI: 10.4158/ep-2018-0417.Peer-Reviewed Original ResearchConceptsType 1 diabetesInsulin degludecDiabetic ketoacidosisGlycemic controlCurrent regimenPatient's current regimenRetrospective chart reviewMonths of treatmentBeta-cell functionType 2 diabetesDiabetes-PatientenUltralong durationChart reviewGlycemic targetsBasal insulinHemoglobin A1cGlycemic outcomesMissed dosesOutcome differencesIDegClinical practiceDiabetes struggleDiabetesType 2Degludec
2015
Racial-Ethnic Disparities in Management and Outcomes Among Children With Type 1 Diabetes
Willi SM, Miller KM, DiMeglio LA, Klingensmith GJ, Simmons JH, Tamborlane WV, Nadeau KJ, Kittelsrud JM, Huckfeldt P, Beck RW, Lipman TH. Racial-Ethnic Disparities in Management and Outcomes Among Children With Type 1 Diabetes. Pediatrics 2015, 135: 424-434. PMID: 25687140, PMCID: PMC4533245, DOI: 10.1542/peds.2014-1774.Peer-Reviewed Original ResearchConceptsHispanic participantsEthnic disparitiesSocioeconomic statusDiabetic ketoacidosisHemoglobin A1cT1D Exchange Clinic RegistryMean hemoglobin A1cLarge pediatric cohortOptimal glycemic controlSevere hypoglycemic eventsBlack participantsType 1 diabetesMore Black participantsNon-Hispanic blacksGlycemic controlSevere hypoglycemiaClinic registryClinical outcomesPediatric cohortHypoglycemic eventsDiabetes outcomesTreatment outcomesTherapeutic modalitiesDiabetes managementDiabetes treatment
2014
Insulin pump use in young children in the T1D Exchange clinic registry is associated with lower hemoglobin A1c levels than injection therapy
Blackman SM, Raghinaru D, Adi S, Simmons JH, Ebner‐Lyon L, Chase HP, Tamborlane WV, Schatz DA, Block JM, Litton JC, Raman V, Foster NC, Kollman CR, DuBose SN, Miller KM, Beck RW, DiMeglio LA. Insulin pump use in young children in the T1D Exchange clinic registry is associated with lower hemoglobin A1c levels than injection therapy. Pediatric Diabetes 2014, 15: 564-572. PMID: 24494980, DOI: 10.1111/pedi.12121.Peer-Reviewed Original ResearchConceptsContinuous subcutaneous insulin infusionT1D Exchange Clinic RegistryCross-sectional studyInjection usersClinic registryInitiation of CSIIUse of CSIIInsulin pumpLower hemoglobin A1c levelsDiabetic ketoacidosis eventsHemoglobin A1c levelsSevere hypoglycemia eventsSubcutaneous insulin infusionRetrospective longitudinal studyType 1 diabetesRisk of DKALongitudinal studyYounger age groupsYoung childrenRace/ethnicityKetoacidosis eventsAnnual household incomeT1D durationA1c levelsHemoglobin A1c
2012
Diabetic Ketoacidosis at Diabetes Onset: Still an All Too Common Threat in Youth
Klingensmith GJ, Tamborlane WV, Wood J, Haller MJ, Silverstein J, Cengiz E, Shanmugham S, Kollman C, Wong-Jacobson S, Beck RW, Consortium P. Diabetic Ketoacidosis at Diabetes Onset: Still an All Too Common Threat in Youth. The Journal Of Pediatrics 2012, 162: 330-334.e1. PMID: 22901739, DOI: 10.1016/j.jpeds.2012.06.058.Peer-Reviewed Original ResearchConceptsSevere diabetic ketoacidosisDiabetic ketoacidosisHemoglobin A1cIncidence of DKAInitial hemoglobin A1cNew-onset T1DPediatric Diabetes ConsortiumDiabetes-associated autoantibodiesLife-threatening complicationsOnset of T1DAfrican American raceType 1 diabetesNon-Hispanic CaucasiansClinical characteristicsEligible subjectsDiabetes onsetMean ageFamily historyPrivate health insuranceInclusion criteriaT1DMultivariate analysisYounger ageDemographic informationHealth insurance
2008
Insulin Glargine Versus Intermediate-Acting Insulin as the Basal Component of Multiple Daily Injection Regimens for Adolescents with Type 1 Diabetes Mellitus
Chase HP, Arslanian S, White NH, Tamborlane WV. Insulin Glargine Versus Intermediate-Acting Insulin as the Basal Component of Multiple Daily Injection Regimens for Adolescents with Type 1 Diabetes Mellitus. The Journal Of Pediatrics 2008, 153: 547-553.e3. PMID: 18589448, DOI: 10.1016/j.jpeds.2008.04.063.Peer-Reviewed Original ResearchConceptsInsulin glargineMultiple daily injectionsMultiple daily injection regimensType 1 diabetes mellitusBaseline A1C valuesDaily insulin glargineParallel group comparisonIntermediate acting insulinIntermediate-acting insulinOccurrence of hypoglycemiaPrandial insulin lisproOverall mean changeElevated A1C.MDI regimenMDI regimensBaseline A1CInjection regimensWeek 24Adverse eventsDiabetes mellitusHemoglobin A1cPediatric patientsSevere hypoglycemiaDaily injectionsA1C values